K
8.18
0.27 (3.41%)
| Previous Close | 7.91 |
| Open | 7.90 |
| Volume | 287,477 |
| Avg. Volume (3M) | 704,362 |
| Market Cap | 358,252,672 |
| Price / Book | 2.53 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -3.24 |
| Total Debt/Equity (MRQ) | 3.10% |
| Current Ratio (MRQ) | 7.44 |
| Operating Cash Flow (TTM) | -133.64 M |
| Levered Free Cash Flow (TTM) | -80.19 M |
| Return on Assets (TTM) | -31.08% |
| Return on Equity (TTM) | -49.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Kyverna Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 12.04% |
| % Held by Institutions | 68.57% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Insight Holdings Group, Llc | 30 Sep 2025 | 989,054 |
| Mbb Public Markets I Llc | 30 Sep 2025 | 614,477 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (Wells Fargo, 278.97%) | Buy |
| Median | 25.00 (205.62%) | |
| Low | 20.00 (HC Wainwright & Co., 144.50%) | Buy |
| Average | 25.33 (209.66%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.47 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 04 Dec 2025 | 25.00 (205.62%) | Buy | 7.84 |
| Wells Fargo | 30 Oct 2025 | 31.00 (278.97%) | Buy | 6.75 |
| 08 Oct 2025 | 27.00 (230.07%) | Buy | 7.18 | |
| HC Wainwright & Co. | 27 Oct 2025 | 20.00 (144.50%) | Buy | 7.81 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |